Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease

Journal of Vascular Surgery

Volumn 65, Issue 3, 2017, Pages 720-725

  Zen, Kan ^a   Takahara, Mitsuyoshi ^b   Iida, Osamu ^c   Soga, Yoshimitsu ^d   Kawasaki, Daizo ^e   Nanto, Shinsuke ^b   Yokoi, Hiroyoshi ^f   Matoba, Satoaki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KANSAI ROSAI HOSPITAL   (Japan)

^d KOKURA MEMORIAL HOSPITAL   (Japan)

^e Morinomiya Hospital   (Japan)

^f FUKUOKA SANNO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; THIENOPYRIDINE DERIVATIVE; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; PACLITAXEL; TETRAZOLE DERIVATIVE;

AGED; ANGIOGRAPHY; ARTERY LESION; ASYMPTOMATIC DISEASE; CHRONIC TOTAL OCCLUSION; CONFERENCE PAPER; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DIABETES MELLITUS; DIALYSIS; DRUG ELUTING CARDIOVASCULAR STENT; DUAL ANTIPLATELET THERAPY; DYSLIPIDEMIA; FEMALE; FEMORAL ARTERY; FEMOROPOPLITEAL LESION; FOLLOW UP; HUMAN; HYPERTENSION; IN-STENT RESTENOSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK SYSTOLIC VELOCITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VASCULAR PATENCY; ADVERSE EFFECTS; CLINICAL TRIAL; COMPLICATION; DEVICES; DIAGNOSTIC IMAGING; DRUG EFFECTS; DRUG ELUTING STENT; DUPLEX DOPPLER ULTRASONOGRAPHY; ENDOVASCULAR SURGERY; JAPAN; MIDDLE AGED; ODDS RATIO; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROPENSITY SCORE; PROSTHESIS DESIGN; RECURRENT DISEASE; REGISTER; RISK FACTOR; STATISTICAL MODEL; STENOSIS, OCCLUSION AND OBSTRUCTION; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR AGENTS; CONSTRICTION, PATHOLOGIC; DRUG-ELUTING STENTS; ENDOVASCULAR PROCEDURES; FEMALE; FEMORAL ARTERY; HUMANS; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; POPLITEAL ARTERY; PROPENSITY SCORE; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RECURRENCE; REGISTRIES; RISK FACTORS; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, DUPLEX; VASCULAR PATENCY;

EID: 85009265650     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2016.10.098     Document Type: Conference Paper

References (18)

1. 1 Dake, M.D., Ansel, G.M., Jaff, M.R., Ohki, T., Saxon, R.R., Smouse, H.B., et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 4 (2011), 495–504.
2. 2 Dake, M.D., Ansel, G.M., Jaff, M.R., Ohki, T., Saxon, R.R., Smouse, H.B., et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol 61 (2013), 2417–2427.
3. 3 Iida, O., Takahara, M., Soga, Y., Nakano, M., Yamauchi, Y., Zen, K., et al. 1-year results of the ZEPHYR Registry (Zilver PTX for the femoral artery and proximal popliteal artery): predictors of restenosis. JACC Cardiovasc Interv 8 (2015), 1105–1112.
4. 4 Fujihara, M., Utsunomiya, M., Higashimori, A., Yokoi, Y., Nakamura, M., Outcomes of Zilver PTX stent implantation for the treatment of complex femoropopliteal artery disease. Heart Vessels 31 (2016), 152–157.
5. 5 Sudo, T., Tachibana, K., Toga, K., Tochizawa, S., Inoue, Y., Kimura, Y., et al. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 59 (2000), 347–356.
6. 6 Kimura, Y., Tani, T., Kanbe, T., Watanabe, K., Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 35 (1985), 1144–1149.
7. 7 Kawamura, K., Watanabe, K., Kimura, Y., Effect of cilostazol, a new antithrombotic drug, on cerebral circulation. Arzneimittelforschung 35 (1985), 1149–1154.
8. 8 Shintani, S., Watanabe, K., Kawamura, K., Mori, T., Tani, T., Toba, Y., et al. General pharmacological properties of cilostazol, a new antithrombotic drug. Part II: effect on the peripheral organs. Arzneimittelforschung 35 (1985), 1163–1172.
9. 9 Takahashi, S., Oida, K., Fujiwara, R., Maeda, H., Hayashi, S., Takai, H., et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Phamacol 20 (1992), 900–906.
10. 10 Thompson, P.D., Zimet, R., Forbes, W.P., Zhang, P., Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 90 (2002), 1314–1319.
11. 11 Biondi-Zoccai, G.G., Lotrionte, M., Anselmino, M., Moretti, C., Agostoni, P., Testa, L., et al. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J 155 (2008), 1081–1089.
12. 12 Douglas, J.S. Jr., Holmes, D.R. Jr., Kereiakes, D.J., Grines, C.L., Block, E., Ghazzal, Z.M., et al., Cilostazol for Restenosis Trial (CREST) Investigators. Coronary stent restenosis in patients treated with cilostazol. Circulation 112 (2005), 2826–2832.
13. 13 Kubota, Y., Kichikawa, K., Uchida, H., Maeda, M., Nishimine, K., Makutani, S., et al. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study. Invest Radiol 30 (1995), 532–537.
14. 14 Iida, O., Yokoi, H., Soga, Y., Inoue, N., Suzuki, K., Yokoi, Y., et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation 127 (2013), 2307–2315.
15. 15 Austin, P.C., Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10 (2011), 150–161.
16. 16 Dake, M.D., Ansel, G.M., Jaff, M.R., Ohki, T., Saxon, R.R., Smouse, H.B., et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX Randomized Trial. Circulation 133 (2016), 1472–1483.
17. 17 Suh, J.W., Lee, S.P., Park, K.W., Lee, H.Y., Kang, H.J., Koo, B.K., et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy on ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 57 (2011), 280–289.
18. 18 Hiatt, W.R., Money, S.R., Brass, E.P., Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg 47 (2008), 330–336.